Both HIV-1 integrase (IN) and the central catalytic domain of IN (IN-CCD) catalyze the disintegration reaction in vitro.In this study,IN and IN-CCD proteins were expressed and purified,and a high-throughput format enzyme-linked immunosorbent assay (ELISA) was developed for the disintegration reaction.IN exhibited a marked preference for Mn2+ over Mg2+ as the divalent cation cofactor in disintegration.Baicalein,a known IN inhibitor,was found to be an IN-CCD inhibitor.The assay is sensitive and specific for the study of disintegration reaction as well as for the in vitro identification of antiviral drugs targeting IN,especially targeting IN-CCD.
HE HongQiu,LIU Bin,ZHANG XiaoYi,CHEN WeiZu & WANG CunXin College of Life Science and Bioengineering,Beijing University of Technology,Beijing 100124,China
HIV-1整合酶是HIV-1生命周期中必不可少的酶之一,已成为目前最具潜力的抗HIV药物设计的靶点之一。2007年,Merk公司研发的MK-5108作为首个整合酶抑制剂药物被美国食品药物管理局批准上市,标志着整合酶抑制剂研究的重大突破,也激发了抗HIV-1整合酶抑制剂研究的新一轮高潮。计算机辅助药物设计(computer-aided drug design,CADD)具有效率高、成本低等特点,基于计算机辅助手段合理药物设计已取得了很大的进展。文章综述了近几年来计算机辅助设计抗HIV整合酶抑制剂及耐药机理方面的研究进展。
